MapLight Therapeutics

MapLight Therapeutics

MapLight Therapeutics was co-founded in 2018 by CEO Christopher McHugh and scientific co-founders including Dr. Karl Deisseroth, the Stanford neuroscientist who pioneered optogenetics. The firm is built on the premise that many central nervous system disorders — from schizophrenia to Parkinson's disease — stem from dysfunction in overlapping brain circuits. This thesis flips the traditional symptom-based classification for a circuitry-based target discovery platform. The founding team combined Deisseroth's neurobiology expertise with McHugh's operational background in biotech venture creation. The firm's strategy centers on drug development for neuropsychiatric and movement disorders. Its platform identifies malfunctioning neural circuits and develops small-molecule therapeutics to restore normal function. MapLight's pipeline spans multiple stages: ML-007, a muscarinic receptor modulator for schizophrenia and Alzheimer's-related psychosis, reached Phase 2 trials in 2024. A second asset targets Parkinson's disease dyskinesias. The firm operates as an R&D-focused biopharma company rather than a fund, drawing investment from crossover and venture firms. Confirmed backers include 5AM Ventures, Cowen Healthcare Investments, Novo Holdings, and Mission BioCapital. Geographic focus is US-based clinical development with global pharma partnership ambitions. MapLight secured a $225 million Series C financing round in October 2023 (per the firm's official communications, 2023). The raise, co-led by Novo Holdings and Cowen Healthcare Investments, ranks among the largest private biotech financings of that year. Proceeds fund late-stage clinical development of ML-007. The firm does not disclose total assets under management or a traditional deployment model, but its financing track record — spanning venture capital equity rounds — reflects a capital-efficient, milestone-driven structure typical of private biotech companies rather than platform investment vehicles. Structurally, MapLight differs from many early-stage neuroscience companies by building a platform around circuitry biology rather than a single lead molecule. The presence of Deisseroth on the scientific advisory board provides a research foundation that few CNS startups can replicate. The firm's governance reflects a conventional biotech board structure with venture investors holding seats, making it distinct from family-office-backed or single-asset vehicles that often populate the neuroscience space.